These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 8152567)

  • 21. Effects of antidepressant treatment on thyrotropin-releasing hormone stimulation, growth hormone response to L-DOPA, and dexamethasone suppression tests in major depressive patients.
    Esel E; Kartalci S; Tutus A; Turan T; Sofuoglu S
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):303-9. PubMed ID: 14751427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GH response to oral and intravenous glucose load in acromegalic patients.
    Mancini A; Zuppi P; Fiumara C; Valle D; Conte G; Fabrizi ML; Sammartano L; Anile C; Maira G; De Marinis L
    Horm Metab Res; 1995 Jul; 27(7):322-5. PubMed ID: 7590615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pituitary adenomas of patients with acromegaly express thyrotropin-releasing hormone receptor messenger RNA: cloning and functional expression of the human thyrotropin-releasing hormone receptor gene.
    Yamada M; Monden T; Satoh T; Satoh N; Murakami M; Iriuchijima T; Kakegawa T; Mori M
    Biochem Biophys Res Commun; 1993 Sep; 195(2):737-45. PubMed ID: 8396925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological characteristics of growth hormone-producing pituitary adenomas are different according to responsiveness to thyrotropin-releasing hormone.
    Arita H; Kinoshita M; Oshino S; Kitamura T; Otsuki M; Kasayama S; Shimokawa T; Shimomura I; Yoshimine T; Saitoh Y
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2741-7. PubMed ID: 22569237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transient appearance of a provocative growth hormone response to L-dopa following incomplete adenomectomy in an acromegalic patient.
    Takahara J; Yakushiji W; Yamuchi J; Miyoshi M; Hosogi H
    J Clin Endocrinol Metab; 1977 Mar; 44(3):599-602. PubMed ID: 838854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly.
    Biermasz NR; Smit JW; van Dulken H; Roelfsema F
    Clin Endocrinol (Oxf); 2002 Mar; 56(3):313-9. PubMed ID: 11940042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involvement of a dopaminergic mechanism in the response of growth hormone to thyrotropin releasing hormone in patients with major depression.
    Marchesi C; Gnudi A; Chiodera P; De Risio C; Fava A; Dasso L; De Ferri A; Guerra M; Coiro V
    Pharmacopsychiatry; 1987 Mar; 20(2):64-6. PubMed ID: 3108910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly.
    Giustina A; Bresciani E; Bussi AR; Bollati A; Bonfanti C; Bugari G; Chiesa L; Giustina G
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1333-40. PubMed ID: 7536207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
    Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.
    Lissoni P; Malugani F; Casu M; Bukovec R; Egardi R; Bordin V; Fumagalli E; Mengo S; Gardani G
    Neuro Endocrinol Lett; 2002 Feb; 23(1):61-3. PubMed ID: 11880864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: in vivo and in vitro studies.
    Colao A; Merola B; Ferone D; Calabrese MR; Longobardi S; Spaziante R; Di Renzo G; Annunziato L; Lombardi G
    Eur J Endocrinol; 1994 Jul; 131(1):14-9. PubMed ID: 8038903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenylate cyclase of GH and ACTH producing tumors of human: activation by non-specific hormones and other bioactive substances.
    Matsukura S; Kakita T; Hirata Y; Yoshimi H; Fukase M
    J Clin Endocrinol Metab; 1977 Feb; 44(2):392-7. PubMed ID: 190256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro effect of dopamine and L-dopa on prolactin and growth hormone release from human pituitary adenomas.
    Peillon F; Cesselin F; Bression D; Zygelman N; Brandi AM; Nousbaum A; Mauborgne A
    J Clin Endocrinol Metab; 1979 Nov; 49(5):737-41. PubMed ID: 489713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paradoxical response of growth hormone to peptide histidine methionine in acromegaly: comparison with the effects of thyrotropin-releasing hormone and vasoactive intestinal peptide.
    Watanobe H; Sasaki S; Sone K; Takebe K
    J Clin Endocrinol Metab; 1991 May; 72(5):982-5. PubMed ID: 1902488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of thyrotropin-releasing hormone and bromoergocriptine on growth hormone and prolactin secretion in perfused pituitary adenoma tissues of acromegaly.
    Ishibashi M; Yamaji T
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1251-6. PubMed ID: 122426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Changes in endocrine status in cancer patients and the effect of chemotherapy on endocrine functions].
    Kamijo K; Kawasaki K; Sato M; Yachi A
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):755-62. PubMed ID: 2436576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression study of thyrotropin releasing hormone (TRH) receptor using RT-PCR: relationship to clinical and immunohistochemical phenotypes in a series of human pituitary adenomas.
    Igarashi-Migitaka J; Yamada S; Hara M; Sano T; Ozawa Y; Ohtani-Kaneko R; Hirata K
    Endocr J; 2003 Aug; 50(4):459-67. PubMed ID: 14599121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The GH-releasing hormone (GHRH) test in acromegaly before and after adenomectomy.
    Giusti M; Lomeo A; Monachesi M; Mazzocchi G; Attanasio R; Sessarego P; Mignone D; Del Monte P; Giordano G
    J Endocrinol Invest; 1987 Apr; 10(2):143-51. PubMed ID: 3108356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.